Healthcare
Lee's Pharmaceutical Holdings Limited(LPCUF)
Live Price
Offline$0.1903
+0.00% today
1Y Change
+1.12%
Window
Jun 25, 2025 → Jun 18, 2026
- Market Cap
- $660.00M
- Revenue Growth
- +2.5%
- EPS Growth
- 0.0%
- Dividend Yield
- 4.2%
Coverage: 252 bars · Jun 25, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Lee's Pharmaceutical Holdings Limited (LPCUF) is a Healthcare stock with a market cap of $660.00M and listed on OTC. The stock last traded around $0.19 and up 1.1% across the available one-year price window (Jun 25, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +2.5%, EPS growth of 0.0%, a dividend yield of 4.2%. What stands out right now is revenue +2.5%, EPS 0.0%, free cash flow +194.2% with operating margin 4.9% and ROIC 2.2%. The dividend matters to the case here, with a current yield around 4.2%. Valuation is more restrained than many high-expectation growth names at P/E 6.2 and price/sales 0.4. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines LPCUF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+2.5% vs +7.6% peer median
Operating Margin
Below sector median
+4.9% vs +19.4% peer median
P/E
Below sector median
6.2 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The setup is mixed rather than one-directional
Revenue is +2.5% and EPS is 0.0%, while operating margin sits near 4.9%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 4.2%, which matters if the thesis depends on income as much as growth.
Benchmark Edge
LPCUF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
LPCUF
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
LPCUF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for LPCUF and SPY.
Company Overview
Lee's Pharmaceutical Holdings Limited
Other OTC
Lee's Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products primarily in the People's Republic of China. The company focuses on various disease areas, including cardiovascular, woman health, paediatrics, rare diseases, oncology, dermatology, obstetrics, and urology. It operates through Proprietary and Generic Products; and Licensed-In Products segments. The Proprietary and Generic Products segment manufactures and sells self-developed and generic pharmaceutical products, such as Livaracine to treat blood clots and deep vein thrombosis; Yallaferon for viral infection; Slounase for hemostasis; Eyprotor for corneal ulcers; Treprostinil injection for pulmonary arterial hypertension; fondaparinux sodium injection for deep vein thrombosis; and Sodium Phenylbutyrate Granules to treat Urea cycle disorders. The Licensed-In Products segment trades in licensed-in pharmaceutical products, including Carnitene for the treatment of carnitine deficiency; Aloxi and Sancuso for chemotherapy induced nausea and vomiting; Bredinin to treat Immunosuppression in renaltransplantation; Centraxal Plus for acute otitis media with tympanostomy tubes; Episil to treat oral mucositis pain; Ferplex to treat iron deficiency anemia; and Gaslon N for gastric ulcer and gastritis. This segment also offers Intrarosa for vulvovaginal atrophy; Levocarnitine oral solution to treat primary and secondary carnitine deficiency; Mictonorm for urinary incontinence; Natulan for Stage III and IV Hodgkin's disease; Omacor to treat Omega-3-acid ethyl esters; Zanidip and Rasilez for hypertension; Readyfusor for post-operative pain management; Teglutik to treat Amyotrophic lateral sclerosis; Trittico for insomnia/depression; Unidrox for urinary and respiratory tract infections; Dicoflor and VSL#3 for probiotics; and Zingo for topical local analgesics. The company was founded in 1994 and is headquartered in Sha Tin, Hong Kong.
- Leadership
- Siu Fong Lee
- IPO Date
- Jul 16, 2021
- Employees
- 1.0k
- Street Address
- Building 20E
- Mailing
- Sha Tin
- Region
- Sha Tin, HK
- Reporting Currency
- USD
- Investor Line
- 852 2314 1282
- Last Updated
- May 1, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 6.2
- EV/EBITDA
- 2.2
- Price/Sales
- 0.4
- Price/Book
- 0.3
Growth
- Revenue
- +2.5%
- EPS
- 0.0%
- Free Cash Flow
- +194.2%
Profitability
- Gross Margin
- 51.5%
- Operating Margin
- 4.9%
- Net Margin
- 5.9%
- ROE
- 5.7%
- ROIC
- 2.2%
Balance Sheet
- Debt/Equity
- 0.15
- Current Ratio
- 1.03
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.